Transforming fundamental discoveries into tomorrow's cancer therapies.

Targeting novel biology in oncology with a focus on translating academic discovery into first-in-class small molecule therapeutics.

Developing next-generation immuno-oncology and targeted degradation approaches with the potential to overcome resistance and broaden patient benefit.

Enabling high-resolution single-cell analysis to support discovery and development of precision oncology therapeutics.

Focused on developing differentiated therapies aimed at hard-to-treat solid tumors.

Engineering cell therapies designed to modulate the tumor microenvironment and enhance durable responses.

Developing ultrasensitive liquid biopsy solutions for the detection and monitoring of cancer through circulating tumor DNA.

Therapeutic programs aimed at addressing key drivers of tumor progression and resistance.

Building a pipeline of precision therapies based on deep insights into cancer genetics and biology.

Developing immuno-oncology therapies designed to modulate immune responses and enhance anti-tumor activity.

Pursuing innovative therapeutic approaches to deliver meaningful benefit in difficult-to-treat cancers.

Early-stage stealth oncology company advancing a novel approach to treating cancer. Further details to be disclosed at a later stage.